Pharmacokinetic properties of rituximab

Reviews on Recent Clinical Trials

Volumn 3, Issue 1, 2008, Pages 22-30

  Rodriguez, Jose ^a   Gutierrez, Antonio ^a  

^a HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

Author keywords

Lymphoma; Pharmacokinetic; Rituximab; Treatment

Indexed keywords

CD20 ANTIGEN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLT3 LIGAND; FLUDARABINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; I KAPPA B; MITOXANTRONE; PREDNISOLONE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPLEMENT DEPENDENT CYTOTOXICITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG METABOLISM; DRUG MONITORING; DRUG POTENTIATION; FOLLICULAR LYMPHOMA; HUMAN; LYMPHOMA; MANTLE CELL LYMPHOMA; MONOTHERAPY; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; LYMPHOMA;

EID: 39549092399     PISSN: 15748871     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488708783330495     Document Type: Article

References (79)

1. Plosker GL, Figgitt DP. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 2003; 63(8): 803-43.
2. Riley JK, Sliwkowski MX. CD20: a gene in search of a function. Semin Oncol 2000; 27(6 Suppl 12): 17-24.
3. Cragg MS, Walshe CA, Ivanov AO, Glennie MJ. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun 2005; 8: 140-74.
4. Villamor N, Montserrat E, Colomer D. Mechanism of action and resistance to monoclonal antibody therapy. Semin Oncol 2003; 30(4): 424-33.
5. Demidem A, Lam T, Alas S, Hariharan K, Hanna N, Bonavida B. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 1997; 12(3): 177-86.
6. Alas S, Bonavida B. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lympboma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of BcI-2 and sensitization to cytotoxic drugs. Cancer Res 2001; 61(13): 5137-44.
7. Alas S, Ng CP, Bonavida B. Rituximab modifies the cisplatin-mitochondrial signaling pathway, resulting in apoptosis in cisplatin-resistant non-Hodgkin's lymphoma. Clin Cancer Res 2002; 8(3): 836-45.
8. Emmanouilides C, Jazirehi AR, Bonavida B. Rituximab-mediated sensitization of B-non-Hodgkin's lymphoma (NHL) to cytotoxicity induced by paclitaxel, gemcitabine, and vinorelbine. Cancer Biother Radiopharm 2002; 17(6): 621-30.
9. Jazirehi AR, Gan XH, De Vos S, Emmanouilides C, Bonavida B. Rituximab (anti-CD20) selectively modifies Bcl-xL and apoptosis protease activating factor-1 (Apaf-1) expression and sensitizes human non-Hodgkin's lymphoma B cell lines to paclitaxel-induced apoptosis. Mol Cancer Ther 2003; 2(11): 1183-93.
10. Jazirehi AR, Vega MI, Chatterjee D, Goodglick L, Bonavida B. Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab. Cancer Res 2004; 64(19): 7117-26.
11. Vega MI, Huerta-Yepez S, Jazirehi AR, Garban H, Bonavida B. Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis. Oncogene 2005; 24(55): 8114-27.
12. Jazirehi AR, Huerta-Yepez S, Cheng G, Bonavida B. Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis. Cancer Res 2005; 65(1): 264-76.
13. Jazirehi AR, Bonavida B. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization. and therapeutic intervention. Oncogene 2005; 24(13): 2121-43.
14. Berinstein NL, Grillo-Lopez AJ, White CA, et al. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1998; 9(9): 995-1001.
15. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16(8): 2825-33.
16. Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90(6): 2188-95.
17. Piro LD, White CA, Grillo-Lopez AJ, et al. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1999; 10(6): 655-61.
18. Maloney DG, Liles TM, Czerwinski DK, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994; 84(8): 2457-66.
19. Mangel J, Bucktein R, Imrie K, et al. Pharmacokinetic study of patients with follicular or mantle cell lymphoma treated with rituximab as 'in vivo purge' and consolidative immunotherapy following autologous stem cell transplantation. Ann Oncol 2003; 14(5): 758-65.
20. Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999; 17(1): 268-76.
21. Regazzi MB, Iacona I, Avanzini MA, et al. Pharmacokinetic behavior of rituximab: a study of different schedules of administration for heterogeneous clinical settings. Ther Drug Monit 2005; 27(6): 785-92.
22. McLaughlin P, Hagemeister FB, Grillo-Lopez AJ. Rituximab in indolent lymphoma: the single-agent pivotal trial. Semin Oncol 1999; 26(5 Suppl 14): 79-87.
23. Igarashi T, Kobayashi Y, Ogura M, et al. Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study. Ann Oncol 2002; 13(6): 928-43.
24. Ruhstaller TW, Amsler U, Cerny T. Rituximab: active treatment of central nervous system involvement by non-Hodgkin's lymphoma? Ann Oncol 2000; 11(3): 374-5.
25. Venugopal P, Sivaraman S, Huang XK, Nayini J, Gregory SA, Preisler HD. Effects of cytokines on CD20 antigen expression on tumor cells from patients with chronic lymphocytic leukemia. Leuk Res 2000; 24(5): 411-5.
26. Mangel J, Leitch HA, Connors JM, et al. Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis. Ann Oncol 2004; 15(2): 283-90.
27. Tobinai K, Igarashi T, Itoh K, et al. Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma. Ann Oncol 2004; 15(5): 821-30.
28. Manshouri T, Do KA, Wang X, et al. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood 2003; 101 (7): 2507-13.
29. Jilani I, O'Brien S, Manshuri T, et al. Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia. Blood 2003; 102(10): 3514-20.
30. Gordan LN, Grow WB, Pusateri A, Douglas V, Mendenhall NP, Lynch JW. Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders. J Clin Oncol 2005; 23(6): 1096-102.
31. Buysmann S, Hack CE, van Diepen FN, Surachno J, ten Berge IJ. Administration of OKT3 as a two-hour infusion attenuates first-dose side effects. Transplantation 1997; 64(11): 1620-3.
32. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000; 6(4): 443-6.
33. Koene HF, Kleijer M, Algra J, Roos D, von dem Borne AE, de Haas M. Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood 1997; 90(3): 1109-14.
34. Gamadia LE, Rentenaar RJ, Baars PA, et al. Differentiation of cytomegalovirus-specific CD8(+) T cells in healthy and immuno-suppressed virus carriers. Blood 2001; 98(3): 754-61.
35. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003; 21(21): 3940-7.
36. Ghielmini M. Multimodality therapies and optimal schedule of antibodies: rituximab in lymphoma as an example. Hematology Am Soc Hematol Educ Program 2005: 321-8.
37. Golay J, Zaffaroni L, Vaccari T, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 2000; 95(12): 3900-8.
38. Bellosillo B, Villamor N, Lopez-Guillermo A, et al. Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species. Blood 2001; 98(9): 2771-7.
39. Bannerji R, Kitada S, Flinn IW, et al. Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance. J Clin Oncol 2003; 21(8): 1466-71.
40. Janas E, Priest R, Wilde JI, White JH, Malhotra R. Rituxan (anti-CD20 antibody)-induced translocation of CD20 into lipid rafts is crucial for calcium influx and apoptosis. Clin Exp Immunol 2005; 139(3): 439-46.
41. Pierce SK. Lipid rafts and B-cell activation. Nat Rev Immunol 2002; 2(2): 96-105.
42. Gutierrez A, Rodriguez J, Martinez J, et al. Pathogenic study of anti-CD20 infusion-related severe refractory shock in diffuse large B-cell lymphoma. Leuk Lymphoma 2006; 47(1): 111-5.
43. Shan D, Ledbetter JA, Press OW. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother 2000; 48(12): 673-83.
44. Cardarelli PM, Quinn M, Buckman D, et al. Binding to CD20 by anti-B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines. Cancer Immunol Immunother 2002; 51(1): 15-24.
45. Harjunpaa A, Taskinen M, Nykter M, et al. Differential gene expression in non-malignant tumour microenvironment is associated with outcome in follicular lymphoma patients treated with rituximab and CHOP. Br J Haematol 2006; 135(1): 33-42.
46. Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood 2004; 104(9): 2635-42.
47. Deans JP, Li H, Polyak MJ. CD20-mediated apoptosis: signalling through lipid rafts. Immunology 2002; 107(2): 176-82.
48. Semac I, Palomba C, Kulangara K, et al. Anti-CD20 therapeutic antibody rituximab modifies the functional organization of rafts/ microdomains of B lymphoma cells. Cancer Res 2003; 63(2): 534-40.
49. Gong Q, Ou Q, Ye S, et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol 2005; 174(2): 817-26.
50. Vugmeyster Y, Howell K, McKeever K, Combs D, Canova-Davis E. Differential in vivo effects of rituximab on two B-cell subsets in cynomolgus monkeys. Int Immunopharmacol 2003; 3(10-11): 1477-81.
51. Selenko N, Majdic O, Jager U, Sillaber C, Stockl J, Knapp W. Cross-priming of cytotoxic T cells promoted by apoptosis-inducing tumor cell reactive antibodies? J Clin Immunol 2002; 22(3): 124-30.
52. Haidar JH, Shamseddine A, Salem Z, et al. Loss of CD20 expression in relapsed lymphomas after rituximab therapy. Eur J Haematol 2003; 70(5): 330-2.
53. Foran JM, Norton AJ, Micallef IN, et al. Loss of CD20 expression following treatment with rituximab (chimaeric monoclonal anti-CD20): a retrospective cohort analysis. Br J Haematol 2001; 114(4): 881-3.
54. Pickartz T, Ringel F, Wedde M, et al. Selection of B-cell chronic lymphocytic leukemia cell variants by therapy with anti-CD20 monoclonal antibody rituximab. Exp Hematol 2001; 29(12): 1410-6.
55. Jazirehi AR, Vega MI, Bonavida B. Developrnmt of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy. Cancer Res 2007, 67(3): 1270-81.
56. Hainsworth JD, Litchy S, Burris HA 3rd, et al. Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma. J Clin Oncol 2002; 20(20): 4261-7.
57. Ghielmini M. Patient benefits of maintenance immunotherapy. Leuk Res 2006; 30 (Suppl 1): S22-6.
58. Hiddemann W. Rituximab maintenance therapy in follicular lymphoma comes of age. Leuk Res 2006; 30 (Suppl 1): S1-2.
59. Chetie MA, Crank M, Kufert S, Pop I, Vitetta E. Rituximab but not other anti-CD20 antibodies reverses multidrug resistance in 2 B lymphoma cell lines, blocks the activity of P-glycoprotein (P-gp), and induces P-gp to translocate out of lipid rafts. J Immunother (1997) 2006; 29(5): 536-44.
60. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005; 105(4): 1417-23.
61. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005; 106(12): 3725-32.
62. van Oers MH, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lympboma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006; 108(10): 3295-301.
63. Forstpointner R, Dreyling M, Repp R, et al. The addition of ritiximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospectivc randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004; 104(10): 3064-71.
64. Herold M, Haas A, Stock S, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Chn Oncol 2007; 25(15): 1986-92.
65. Lenz G, Dreyling M, Hoster E, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005; 23(9): 1984-92.
66. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346(4): 235-42.
67. Pfreundschuh M, Trumpet L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the Mab Thera International Trial (MInT) Group. Lancet Oncol 2006; 7(5): 379-91.
68. Rossi J, Yang L, Quittet P. Rituximab and GM-CSF, an effective therapy for relapsed/refractory patients with low-grade B-cell lymphoma: correlation between response and dendritic cell subpopulation, mobilized. Blood 2001; 98: 607a.
69. Hernandez-Ilizaliturri FJ, Jupudy V, Reising S, Repasky EA, Czuczman MS. Concurrent administration of granulocyte colony-stimulating factor or granulocyte-monocyte colony-stimulating factor enhances the biological activity of rituximab in a severe combined immunodeficiency mouse lymphoma model. Leuk Lymphoma 2005; 46(12): 1775-84.
70. Olivieri A, Lucesole M, Capelli D, et al. A new schedule of CHOP/ rituximab plus granulocyte-macrophage colony-stimulating factor is an effective rescue for patients with aggressive lymphoma failing autologous stem cell transplantation. Biol Blood Marrow Transplant 2005, 11(8): 627-36.
71. Niitsu N, Hayama M, Okamoto M, et al. Phase I study of Rituximab-CHOP regimen in combination with granulocyte colony-stimulating factor in patients with follicular lymphoma, Clin Cancer Res 2004; 10(12 Pt 1): 4077-82.
72. Portlock CS, O'Connor OA, Straus DJ, et al. Pegylated interferon plus rituximab in advanced stage, indolent lymphoma: is there CD20 antigen upregulation? Leuk Lymphoma 2006; 47(7): 1260-4.
73. Ziller F, Macor P, Bulla R, Sblattero D, Marzari R, Tedesco F. Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59. Eur J Immunol 2005; 35(7): 2175-83.
74. Nagajothi N, Matsui WM, Mukhina GL, Brodsky RA. Enhanced cytotoxicity of rituximab following genetic and biochemical disruption of glycosylphosphatidylinositol anchored proteins. Leuk Lymphoma 2004; 45(4): 795-9.
75. Idusogie EE, Wong PY, Presta LG, et al. Engineered antibodies with increased activity to recruit complement. J Immunol 2001; 166(4): 2571-5.
76. Smolewski P, Duechler M, Linke A, et al. Additive cytotoxic effect of bortezomib in combination with anti-CD20 or anti-CD52 monoclonal antibodies on chronic lymphocytic leukemia cells. Leuk Res 2006; 30(12): 1521-9.
77. O'Brien SM, Kantarjian H, Thomas DA, et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001; 19(8): 2165-70.
78. Hainsworth JD, Litchy S, Barton JH, et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2003; 21(9): 1746-51.
79. Dogan A, Du MQ, Aiello A, et al. Fellicular lymphomas contain a clonally linked but phenotypically distinct neoplastic B-cell population in the interfollicular zone. Blood 1998; 91(12): 4708-14.